[HTML][HTML] New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia
The treatment of acute myeloid leukemia (AML) has evolved over the past few years with the
advent of next-generation sequencing. Targeted therapies alone or in combination with low …
advent of next-generation sequencing. Targeted therapies alone or in combination with low …
[HTML][HTML] Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review
Cellular therapies, including autologous stem cell transplant (ASCT), allogeneic
hematopoietic cell transplantation (alloHCT), and chimeric antigen receptor-(CAR-) T cell …
hematopoietic cell transplantation (alloHCT), and chimeric antigen receptor-(CAR-) T cell …
Optimizing outcomes in secondary AML
A Matthews, KW Pratz - Hematology, 2022 - ashpublications.org
Acute myeloid leukemia (AML) secondary to antecedent hematologic disorder or prior
therapeutics for cancer represent a diverse group of leukemias often associated with inferior …
therapeutics for cancer represent a diverse group of leukemias often associated with inferior …
Older adults with newly diagnosed AML: hot topics for the practicing clinician
C Lai, RS Bhansali, EJ Kuo, G Mannis… - American Society of …, 2023 - ascopubs.org
Over the past decade, our understanding of AML pathogenesis and pathophysiology has
improved significantly with mutational profiling. This has led to translational advances in …
improved significantly with mutational profiling. This has led to translational advances in …
[HTML][HTML] Real-world experience with CPX-351 in high-risk acute myeloid leukemia
Abstract CPX-351, a dual-drug liposomal encapsulation of daunorubicin/cytarabine, was
approved for newly diagnosed therapy-related acute myeloid leukemia (AML) and AML with …
approved for newly diagnosed therapy-related acute myeloid leukemia (AML) and AML with …
Advancements and Challenges in the Treatment of AML
The therapeutic arsenal for the management of AML has expanded significantly in recent
years. Before 2017, newly diagnosed AML was treated with either standard cytarabine-and …
years. Before 2017, newly diagnosed AML was treated with either standard cytarabine-and …
[HTML][HTML] Novel insights and therapeutic approaches in secondary AML
Secondary acute myeloid leukemia (sAML) presents as a complex and multifaceted
ensemble of disorders, positioning itself as both a challenge and an intriguing frontier within …
ensemble of disorders, positioning itself as both a challenge and an intriguing frontier within …
Transplantation and Cellular Therapy for Older Adults—The MSK Approach
Abstract Purpose of Review Hematologic malignances more commonly affect older
individuals and often present with advanced, higher risk disease than younger patients …
individuals and often present with advanced, higher risk disease than younger patients …
Therapy-related myeloid malignancies in patients with multiple myeloma.
T Kubicki, M Adamska, K Żyłka… - Acta Haematologica …, 2024 - journals.viamedica.pl
The significant advances in the efficacy of myeloma treatment in recent years have brought
greater focus to the issues of long-term therapy complications. Therapy-related myeloid …
greater focus to the issues of long-term therapy complications. Therapy-related myeloid …
Myeloid neoplasms post cytotoxic therapy: epidemiology, pathogenesis outcomes, prognostic factors, and treatment options
J Ma, Y Wang - Annals of Medicine, 2024 - Taylor & Francis
Myeloid neoplasms post cytotoxic therapy (MN-pCT) are a category includes AML, MDS,
and MDS/MPN arising in patients exposed to cytotoxic (DNA-damaging) therapy for an …
and MDS/MPN arising in patients exposed to cytotoxic (DNA-damaging) therapy for an …